John Sullivan is InSight’s Vice President of Research and Development. Mr. Sullivan has managed technical teams and developed medical devices for more than 20 years. Prior to joining IST, Mr. Sullivan served as Vice President of Quality and Engineering at TransMedics, Inc., with responsibilities for new product introduction (resulting in 3 PMA approvals and release to international markets), direction of software, mechanical and electrical development, Quality Assurance and Quality Control, Field Service and Sustaining engineering, and IT. Mr. Sullivan has an additional 10 years of management and development experience with startups and established companies, including Siemens, Juniper Networks, ViaSat and Raytheon. Mr. Sullivan is PMP certified, earned a Bachelors degree in Electrical Engineering and Computer Science at Princeton University, and a Masters of Science in Computer Engineering at Boston University.

Marybeth Gamber, BA, is InSight’s acting Regulatory Affairs and Quality Assurance executive. She is currently Founder of her own regulatory, clinical affairs and quality assurance consulting group.   Her responsibilities include leading the development of IST’s regulatory and clinical strategies to support product development programs and oversee quality assurance. Previously, Ms. Gamber worked AuST Group, Boston Biomedical Associates, Boston Scientific Corp, Acumen Medical, Concentric Medical and Baachus Vascular with increasing roles and responsibilities. As IST’s acting head of Regulatory Affairs, she will direct/coordinate regulatory activities consistent with established company and management goals and objectives. Key experience and qualifications include preparation of regulatory submissions in a wide range of therapeutic areas to support product approvals ((IDE, de novo, HDE, PMA, 510(k); European Union (CE Mark); Australia (Therapeutics Goods Authority); Canada (Health Canada)); FDA liaison representing InSight at meetings; preparation of FDA/client presentations; formulation of innovative regulatory and clinical trial strategies; labeling, promotion, and advertising activities; preparation of pre-clinical product evaluation protocols; training in FDA medical device regulations and overseeing our development partners to ensure IST’s quality systems are in accordance with ISO 13485 and FDA Quality System Regulation.

Bernard E. Lyons, PhD, is InSight’s Executive Chairman and a Board Director. Dr Lyons has over 35 years of experience in the medical device field, and most recently served as President and CEO of Direct Flow Medical – a company he expanded significantly through early development, clinical and later-stage commercial activity while raising several rounds of venture funding. Prior to his Direct Flow experience, Dr Lyons served as President and CEO of Vasca, Inc. a later-stage, privately-held medical device company focused on subcutaneous vascular access ports for hemodialysis treatment in patients with end stage renal disease. Previously, he was President and CEO of CardioClasp, Inc., a development-stage medical device company focused on the treatment of congestive heart failure. Dr Lyons held senior- level positions at Boston Scientific Corporation, where he was the Vice President, Sales and Marketing for Interventional Oncology; Vice President, Sales and Marketing of the Meadox Division; Vice President, Corporate Product Development; and President of Boston Scientific operations in Japan. He is currently a member of the Board of Directors for Minnetronix Medical, Inc., Vitara Medical, Inc., REVA Medical, Inc. and was previously a Director at Creganna-Tactx Medical, Paramit Corp., Vetex Medical Ltd, CrannMed, Ltd., and CairnSurgical, Inc.

Brian C. Wilson, PhD, is InSight’s Co-Founder, Board Director, and Chief Scientific Officer (CSO). He is Senior Scientist at University Health Network (Canada’s largest academic medical consortium) and Professor of Medical Biophysics at University of Toronto. Dr. Wilson worked as a clinical physicist in radiotherapy and radiological imaging for 20+ years. In addition to his clinical responsibilities, he started a research program in biomedical optics in 1982 that he has grown into the Laboratory for Applied Biophotonics that carries out translational research across a spectrum of diagnostic, therapeutic and interventional-guidance applications in oncology, with recent extension to the use of optically-active nanoparticles. His research has been characterized by deep collaborations with a multiplicity of oncologic clinicians, resulting in over 15 published clinical trials, and by industry partnerships with over 30 companies (large and small, national and international, including 3 spin-off companies). Dr. Wilson has for >30 years had a fully-time commitment to developing novel light-based technologies and translating them through pre-clinical models, patenting and collaborative clinical trials into commercialization and, thereby, to clinical adoption and dissemination.

Keith D. Paulsen, PhD, is InSight’s Co-Founder, Board Director, President and Chief Executive Officer. Dr Paulsen is Professor of Biomedical Engineering, Radiology and Surgery at Dartmouth. He is an established NIH-funded investigator with substantial experience in biomedical research, leadership and administration. His research program has been and continues to be highly translational moving innovative technologies, many of which are developed in-house, into early-stage clinical studies. His positions include Director of the Advanced Imaging Center (AIC), which is an NIH-funded infrastructure program to promote and facilitate use of advanced imaging technologies in human and (large) animal subject research; Scientific Director of the Center for Surgical Innovation, also an NIH-funded infrastructure program to promote imaging and image guidance in the setting of surgical intervention; and Co-Director of the Translational Engineering in Cancer Research Program of the NCI-designated Norris Cotton Cancer Center. Dr. Paulsen is a Co-Founer of CairnSurgical, Inc.  He is inventor on 40+ patents/patents-pending and teaches courses in medical device development and surgical innovation.

David W. Roberts, MD, is InSight’s Co-Founder, Board Director and Chief Medical Officer (CMO). He is Professor of Surgery (Neurosurgery), Active Emeritus, Geisel School of Medicine at Dartmouth Hitchcock Medical Center, and Adjunct Professor of Engineering, Thayer School of Engineering, Dartmouth College. Dr. Roberts’ entire professional career has involved the clinical practice of neurosurgery (with a subspecialty focus in stereotaxy and the surgical treatment of brain tumor and epilepsy), resident training, and research primarily in image-guidance and intraoperative fluorescence imaging. In the 1980’s he produced one of the first important patents in image-guided neurosurgery, for frameless stereotaxy, and thereby helped lay the technical and clinical foundations for what is now routinely practiced as “neuro-navigation” or “image-guidance” through commercial systems by Medtronic, BrainLab and Stryker. He remains principal investigator of an NIH-sponsored investigational study involving fluorescence-guided surgical resection, including the development of new technologies to advance the approach. Over the past decade, together with Drs. Keith Paulsen and Brian Wilson, he has investigated quantitative fluorescence guidance in patients using both the point-probe and wide-field imaging approaches. Dr. Roberts is retired from active clinical practice and is devoting his time to InSight Surgical Technologies and the above research activities.